← All trials
NCT06708156
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Nov 27, 2024
- Last posted
- Nov 27, 2024
- Enrollment
- 606
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Seefunge Pharmaceutical Technology Co., Ltd.Collaborator
- Capital Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.